Objective: To explore the association between mild cognitive impairment and hyperuricemia among people aged 55 and above.
Methods: Based on the baseline survey data of "community cohort study on neurological diseases" from 2018 to 2019, 4272 residents aged 55 and above with complete data of individual socioeconomic status, lifestyle, mild cognitive impairment and serum uric acid level were selected as the research objects. The Montreal cognitive assessment(MoCA) was used to evaluate the mild cognitive impairment of the research objects. The relationship between serum uric acid level and MoCA score was analyzed. Multivariate Logistic regression model was used to analyze the association of serum uric acid level and mild cognitive impairment.
Results: The prevalence of cognitive impairment in the normal and high serum uric acid groups were 38. 6% and 38. 4%, respectively. In the normal serum uric acid level group, the serum uric acid level of the non-cognitive impairment group was significantly higher(291. 4 μmol/L)than that of the cognitive impairment group(283. 7 μmol/L)(F=16. 12, P<0. 05), and the MoCA score of the subjects in this group was significantly positively correlated with the serum uric acid level(r=0. 103, P<0. 05). In the hyperuricemia group, no significant difference was found in serum uric acid level between non-cognitive impairment group(450. 9 μmol/L) and cognitive impairment group(442. 4 μmol/L)(F=2. 44, P>0. 05), and there was no correlation between MoCA score and serum uric acid level(r=0. 064, P>0. 05). Logistic regression analysis showed that hyperuricemia was not a risk factor for cognitive impairment in people aged 55 and above(OR=1. 04, 95% CI 0. 87-1. 25, P=0. 630).
Conclusion: Within the normal range of serum uric acid, appropriate increase of serum uric acid may play a protective role in cognitive impairment. Hyperuricemia has not been found to increase the risk of cognitive impairment in people 55 years and older.
Keywords: cognitive impairment; hyperuricemia; uric acid.